Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Cybin ( (TSE:CYBN) ) is now available.
On August 12, 2025, Cybin Inc. announced an amendment to its convertible note agreement with High Trail Special Situations LLC, originally issued on June 30, 2025. This amendment includes changes to the terms of repayment, interest, and prepayment options, which may impact the company’s financial strategy and stakeholder interests by providing more flexible financial management options.
The most recent analyst rating on (TSE:CYBN) stock is a Buy with a C$114.00 price target. To see the full list of analyst forecasts on Cybin stock, see the TSE:CYBN Stock Forecast page.
Spark’s Take on TSE:CYBN Stock
According to Spark, TipRanks’ AI Analyst, TSE:CYBN is a Underperform.
Cybin’s stock score is significantly impacted by its lack of revenue and continuous financial losses, resulting in a low valuation score. While technical indicators are neutral, positive corporate events indicate potential for future growth. However, current financial challenges remain the dominant concern.
To see Spark’s full report on TSE:CYBN stock, click here.
More about Cybin
Cybin Inc. operates in the biotechnology industry, focusing on developing psychedelic-based therapies and products. The company is engaged in advancing research and development of psychedelic compounds for mental health treatment, aiming to provide innovative solutions in the healthcare sector.
Technical Sentiment Signal: Hold
Current Market Cap: C$1.97M
Find detailed analytics on CYBN stock on TipRanks’ Stock Analysis page.